Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa

Journal of Infectious Diseases

Volumn 203, Issue 10, 2011, Pages 1434-1441

  Dudek, Timothy E ^a,c   Torres Lopez, Ernesto ^a,d   Crumpacker, Clyde ^b   Knipe, David M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d Universidad Autonoma   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HERPES SIMPLEX 2 VACCINE; HERPES SIMPLEX VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENETIC VARIABILITY; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PURIFICATION; SOUTH AFRICA; STRAIN DIFFERENCE; UNITED STATES; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS STRAIN;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; EPITOPES; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PAPILLOMAVIRUS VACCINES; SOUTH AFRICA; UNITED STATES; VERO CELLS; VIRULENCE;

EID: 79955025076     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir047     Document Type: Article

References (32)

1. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008; 86:805-12A.
2. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004; 11(Suppl 1):24A-35A. (Pubitemid 38529332)
3. UNAIDS Programme, Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS, 2008.
4. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: Ystematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83. (Pubitemid 41818117)
5. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: A meta-analysis. J Infect Dis 2002; 185:45-52. (Pubitemid 34043015)
6. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-39.
7. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-71. (Pubitemid 351519816)
8. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptorpositive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886-92.
9. Pebody RG, Andrews N, Brown D, et al. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex TransmInfect 2004; 80:185-91. (Pubitemid 38746192)
10. Xu F, SternbergMR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-73. (Pubitemid 44285373)
11. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: A global review. J Infect Dis 2002; 186(Suppl 1):S3-28. (Pubitemid 35178845)
12. Bowden R, Sakaoka H, Ward R, Donnelly P. Patterns of Eurasian HSV- 1 molecular diversity and inferences of human migrations. Infect Genet Evol 2006; 6:63-74. (Pubitemid 43115688)
13. Dolan A, Jamieson FE, Cunningham C, Barnett BC, McGeoch DJ. The genome sequence of herpes simplex virus type 2. J Virol 1998; 72:2010-21. (Pubitemid 28100755)
14. Norberg P, Kasubi MJ, Haarr L, Bergstrom T, Liljeqvist JA. Divergence and recombination of clinical herpes simplex virus type 2 isolates. J Virol 2007; 81:13158-67. (Pubitemid 350161623)
15. Dudek TE, Knipe DM. Vaccine and new antiviral strategies against herpes simplex virus. In: Weller S, ed. Alpha herpesviruses: Molecular and cellular biology. Norfolk, UK: Caister Academic Press, 2011: 317-50.
16. National Institute of Allergy and Infectious Diseases. Study finds genital herpes vaccine ineffective in women Press release. http:// www.niaid.nih.gov/news/newsreleases/2010/Pages/Herpevac.aspx. Accessed 4 March 2011.
17. Da Costa XJ, Jones CA, Knipe DM. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 1999; 96:6994-8. (Pubitemid 29274998)
18. Hoshino Y, Dalai SK, Wang K, et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005; 79:410-8. (Pubitemid 39648394)
19. van Lint AL, Torres-Lopez E, Knipe DM. Immunization with a replication- defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. Virology 2007; 368:227-31. (Pubitemid 350016230)
20. Spang AE, Godowski PJ, Knipe DM. Characterization of herpes simplex virus 2 temperature-sensitive mutants whose lesions map in or near the coding sequences for the major DNA-binding protein. J Virol 1983; 45:332-42.
21. Da Costa XJ, Kramer MF, Zhu J, Brockman MA, Knipe DM. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 2000; 74:7963-71. (Pubitemid 30641640)
22. Rawls WE, Laurel D, Melnick JL, Glicksman JM, Kaufman RH. A search for viruses in smegma, premalignant and early malignant cervical tissues. The isolation of herpesviruses with distinct antigenic properties. Am J Epidemiol 1968; 87:647-55.
23. Ejercito PM, Kieff ED, Roizman B. Characterization of herpes simplex virus strains differing in their effect on social behavior of infected cells. J Gen Virol 1968; 2:357-64.
24. Chatis PA, Crumpacker CS. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. Virology 1991; 180:793-7.
25. Lai W, Chen CY, Morse SA, et al. Increasing relative prevalence of HSV-2 infection among men with genital ulcers from a mining community in South Africa. Sex Transm Infect 2003; 79:202-7. (Pubitemid 36723960)
26. Da Costa XJ, Bourne N, Stanberry LR, Knipe DM. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital herpes. Virology 1997; 232:1-12. (Pubitemid 27244457)
27. Morrison LA, Da Costa XJ, Knipe DM. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 1998; 243:178-87. (Pubitemid 28384182)
28. Dudek T, Mathews LC, Knipe DM. Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 2008; 372:165-75.
29. Hoshino Y, Pesnicak L, Dowdell KC, et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 2009; 200:1088-95.
30. Morrison LA. Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells. Virology 2008; 376:205-10.
31. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998; 101:1500-8. (Pubitemid 28166848)
32. Mitchell WJ, Deshmane SL, Dolan A, McGeoch DJ, Fraser NW. Characterization of herpes simplex virus type 2 transcription during latent infection of mouse trigeminal ganglia. J Virol 1990; 64:5342-8. (Pubitemid 20364524)